Induction of deep remission at 1 year in early, biologic naive Crohn’s disease protects against ....

Updated: Dec 29, 2020

Induction of deep remission at 1 year in early, biologic naive Crohn’s disease protects against disease progression regardless of tight disease control or conventional management.

Ungaro RC., et al., published July 2020 in the GASTROENTEROLOGY


Background & Aims

We investigated the effects of inducing deep remission in patients with early Crohn’s disease (CD).

Methods

We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1–0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05–6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period.

Results

Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07–0.31) was significantly associated with a lower risk of major adverse outcome.

Conclusions

In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.


https://www.gastrojournal.org/article/S0016-5085(20)30390-5/fulltext

0 comments

Recent Posts

See All

Inflammatory bowel disease: An Indian perspective

Inflammatory bowel disease: An Indian perspective Jain M, Venkataraman J Published Apr 2021, in the Indian Journal of medical research. Abstract Inflammatory bowel disease (IBD) in recent times is cau